Bi Nan

BiNan is a pre-clinical stage biotechnology company focused on developing high-Z bismuth-based nanoparticles to enhance the efficacy of radiation therapy for cancer treatment. The company's proprietary technology utilizes the high atomic number of bismuth to increase the localized absorption of X-rays within tumors, thereby maximizing therapeutic damage to cancer cells while sparing surrounding healthy tissue. By acting as a potent radiosensitizer, BiNan's nanoparticles aim to overcome radiation resistance in various solid tumors. The company is currently advancing its lead candidates through early-stage development to address unmet needs in oncology.